Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TGTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ublituximab | Multiple Sclerosis | Phase 4 · NCT07225361 | Recruiting |
| Umbralisib (TGR-1202) | Chronic Lymphocytic Leukemia | Phase 2/3 · NCT03801525 | Terminated |
| Bendamustine | Diffuse Large B-Cell Lymphoma | Phase 2/3 · NCT02793583 | Terminated |
| Edralbrutinib (TG-1701) | Non Hodgkin Lymphoma | Phase 1 · NCT03671590 | Terminated |
| Zeripatamig (TG-1801) | CLL | Phase 1 · NCT04806035 | Terminated |
| Azercabtagene Zapreleucel | B-cell Mediated Autoimmune Disorders | Phase 1 · NCT06680037 | Recruiting |
Also used in these trials (approved or third-party drugs, not TGTX's own candidates): Ocrelizumab, Teriflunomide, Venetoclax, Obinutuzumab, Ibrutinib, Fingolimod Hydrochloride, Chlorambucil, Acalabrutinib, Rituximab, Pembrolizumab, Lenalidomide, Cosibelimab (TG-1501).
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TGTX holds $504.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TGTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 21,190,534 | 14.02% | 2026-09-30 |
| Michael S Weiss CEO, Director |
Insider | 9,778,086 | 6.47% | 2026-01-08 |
| State Street Corporation | Institution (13F) | 8,488,874 | 5.62% | 2026-09-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 8,400,210 | 5.56% | 2026-03-31 |
| Vanguard Capital Management LLC | Institution (13F) | 6,256,425 | 4.14% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 3,703,676 | 2.45% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 3,370,273 | 2.23% | 2026-09-30 |
| Shaw D.E. & Co., Inc. | Institution (13F) | 3,279,204 | 2.17% | 2026-09-30 |
| Congress Asset Management Co | Institution (13F) | 2,606,516 | 1.72% | 2026-09-30 |
| Soleus Capital Management, L.P. | Institution (13F) | 2,556,168 | 1.69% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 2,500,759 | 1.65% | 2026-09-30 |
| Sean A Power CFO |
Insider | 798,111 | 0.53% | 2026-01-08 |
Share count 151,147,827 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-10 filed 2026-09-14 |
Charney Laurence N |
Sale (S) | 5,000 | $54.96 | 168,640 |
| 2026-08-07 filed 2026-08-07 |
Charney Laurence N |
Gift (G) | 450 | – | 173,640 |
| 2026-08-07 filed 2026-08-07 |
Charney Laurence N |
Gift (G) | 500 | – | 174,090 |
| 2026-08-06 filed 2026-08-07 |
Charney Laurence N |
Gift (G) | 5,100 | – | 174,590 |
| 2026-06-11 filed 2026-06-15 |
Lonial Sagar |
Option award (A) | 8,325 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TGTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →